Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Intangible Amortization & Impairment

Discontinued — last reported Q4 '24

Segments

By segment

See full
Segment$55.47M0.0%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.13B+17.9%
Enterprise value$845.67M-0.3%
P/E15.1×-6.8×
P/S1.4×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0×0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:AmortizationAndImpairmentOfIntangibleAssets.

The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 27, 2025, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s intangible amortization & impairment.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s intangible amortization & impairment?
Collegium Pharmaceutical, Inc. (COLL) reported intangible amortization & impairment of $55.47M in Q4 2024.
How has Collegium Pharmaceutical, Inc.'s intangible amortization & impairment changed year-over-year?
Collegium Pharmaceutical, Inc.'s intangible amortization & impairment increased by 60.7% year-over-year, from $34.51M to $55.47M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s intangible amortization & impairment?
Over 3 years (2021 to 2024), Collegium Pharmaceutical, Inc.'s intangible amortization & impairment has grown at a 35.0% compound annual growth rate (CAGR), from $67.18M to $165.3M.